The AKR1A1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population of Jurkat human T-lymphocytes, featuring targeted disruption of the AKR1A1 gene. This heterogeneous cell pool bypasses clonal selection, offering a genetically diverse model to examine AKR1A1 loss-of-function effects.
Jurkat cells are an immortalized T-cell line derived from a patient with acute T-cell leukemia, widely used to study T-cell signaling, apoptosis, and leukemogenesis. Their well-defined signaling pathways and rapid growth make them an ideal host for genetic manipulation, enabling dissection of molecular processes relevant to T-cell malignancies.
AKR1A1 encodes an NADPH-dependent aldo-keto reductase that catalyzes the reduction of D-glucuronate to L-gulonate, a key step in the ascorbate biosynthesis pathway, and also reduces a wide range of endogenous and exogenous carbonyl compounds, converting aldehydes and ketones to corresponding alcohols. The enzyme is transcriptionally regulated by the NFE2L2 (Nrf2) transcription factor, which is activated by oxidative or electrophilic stress, thereby linking AKR1A1 to antioxidant response networks. Downstream, AKR1A1 produces L-gulonate and detoxified carbonyl species, interacting with the NADPH cofactor and other aldo-keto reductase superfamily members. Representative pathway components include D-glucuronate, NADPH, UDP-glucose dehydrogenase, and ascorbic acid.
In the Jurkat T-cell leukemia model, disruption of AKR1A1 is anticipated to impair de novo ascorbate synthesis, thereby depleting an essential antioxidant and increasing vulnerability to oxidative stress and carbonyl toxicity. This loss-of-function model may enhance sensitivity to chemotherapeutic agents such as cisplatin and doxorubicin, providing a relevant system to study drug resistance in T-cell malignancies. The heterogeneous polyclonal population allows examination of diverse cellular responses to metabolic and drug-induced stress.
Applying this model, researchers can measure ascorbate levels via quantification assay and aldehyde reductase activity to confirm metabolic disruption, perform drug sensitivity assays using cisplatin or doxorubicin to dissect chemoresistance, and employ ROS detection alongside apoptosis assays to evaluate redox imbalances. Western blotting and RT-qPCR validate AKR1A1 ablation, while metabolomic profiling can uncover broader pathway adaptations. The cells are also suited for screening AKR1A1 inhibitors and investigating T-cell signaling. For further details, contact Ascent Research.
